These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12092461)

  • 1. The use of monoclonal antibodies to restore self-tolerance in established autoimmunity.
    Chatenoud L
    Endocrinol Metab Clin North Am; 2002 Jun; 31(2):457-75, ix. PubMed ID: 12092461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The regulation of autoimmunity through CD4+ T cells.
    Hutchings P; Parish N; O'Reilly L; Dawe K; Roitt IM; Cooke A
    Autoimmunity; 1993; 15 Suppl():21-3. PubMed ID: 8105991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity.
    Chatenoud L
    Curr Opin Organ Transplant; 2009 Aug; 14(4):351-6. PubMed ID: 19610168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
    Chatenoud L; Waldmann H
    Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
    Chatenoud L; Thervet E; Primo J; Bach JF
    Proc Natl Acad Sci U S A; 1994 Jan; 91(1):123-7. PubMed ID: 8278351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
    Chatenoud L
    Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice.
    Drage M; Zaccone P; Phillips JM; Nicoletti F; Dawson J; Andrew Bradley J; Cooke A
    Transplantation; 2002 Sep; 74(5):611-9. PubMed ID: 12352875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance.
    Kuhn C; You S; Valette F; Hale G; van Endert P; Bach JF; Waldmann H; Chatenoud L
    Sci Transl Med; 2011 Feb; 3(68):68ra10. PubMed ID: 21289272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance.
    Chatenoud L; Bach JF
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S73-81. PubMed ID: 16187942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [One step towards restoration of self-tolerance in human autoimmune diseases].
    Chatenoud L
    Med Sci (Paris); 2007 Feb; 23(2):167-71. PubMed ID: 17291426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice.
    Sempé P; Bédossa P; Richard MF; Villà MC; Bach JF; Boitard C
    Eur J Immunol; 1991 May; 21(5):1163-9. PubMed ID: 1828030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymus-dependent monoclonal antibody-induced protection from transferred diabetes.
    Parish NM; Bowie L; Zusman Harach S; Phillips JM; Cooke A
    Eur J Immunol; 1998 Dec; 28(12):4362-73. PubMed ID: 9862373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells.
    Bluestone JA; Tang Q
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14622-6. PubMed ID: 15322272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies.
    Mottram PL; Murray-Segal LJ; Han W; Maguire J; Stein-Oakley AN
    Transpl Immunol; 2002 Jun; 10(1):63-72. PubMed ID: 12182467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.
    Waldron-Lynch F; von Herrath M; Herold KC
    Novartis Found Symp; 2008; 292():146-55; discussion 155-8, 202-3. PubMed ID: 19203097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell receptor-based immunointervention in autoimmune diseases. Therapeutic use of monoclonal antibodies.
    Chatenoud L; Bach JF
    Immunol Ser; 1993; 59():101-16. PubMed ID: 7681694
    [No Abstract]   [Full Text] [Related]  

  • 17. Tolerance to IDDM induced by CD4 antibodies in nonobese diabetic mice is reversed by cyclophosphamide.
    Parish NM; Hutchings PR; Waldmann H; Cooke A
    Diabetes; 1993 Nov; 42(11):1601-5. PubMed ID: 8405701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.
    Guo Z; Wu T; Kirchhof N; Mital D; Williams JW; Azuma M; Sutherland DE; Hering BJ
    Transplantation; 2001 Jun; 71(11):1656-65. PubMed ID: 11435979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD4 monoclonal antibodies in therapy: creation of nonclassical tolerance in the adult.
    Shizuru JA; Alters SE; Fathman CG
    Immunol Rev; 1992 Oct; 129():105-30. PubMed ID: 1361179
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum.
    Maki T; Ichikawa T; Blanco R; Porter J
    Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3434-8. PubMed ID: 1565635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.